- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00985582
Antiviral Therapy for Influenza A H1N1 (SEA032)
Antiviral Treatment in Adults and Children With Novel Influenza A (H1N1) Respiratory Tract Infection - a Clinical, Virological and Pharmacokinetic Study.
The aims of this study are to characterise the clinical efficacy and virological clearance dynamics of orally administered oseltamivir in patients with influenza caused by novel influenza A(H1N1). This research will also contribute to enhancing research capacity in affected countries.
The objectives are to assess the:
- viral replication levels over time in affected patients
- antiviral efficacy of oral oseltamivir
- patterns and compartments of viral shedding, tissue distribution
- innate inflammatory response and relation to viral replication
- kinetics of antibody response
- antiviral sensitivity of influenza viruses at baseline and during oseltamivir treatment using in vitro and molecular methods
- pharmacokinetic characteristics of oseltamivir and oseltamivir carboxylate
- all cause in hospital mortality
- clinical and radiological features, disease course and outcome
- length of stay in hospital
- risk factors associated with development of severe disease and death
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Any patient over 1 year of age who presents to a participating institution with confirmed influenza A and who meets the study inclusion/exclusion criteria may be approached for informed consent. Choice of antiviral is up to the study physician. Children aged 1-6 years and asthmatics should receive oseltamivir. The weight- and age-adjusted dosage used will be that approved for treatment of uncomplicated seasonal influenza, and doses will be administered twice daily for 5 days for patients with normal renal function. All patients who are clinical and/or virologic failures at day 5 will be treated for an additional 5 days of antivirals. After coming off antiviral therapy patients can be discharged at day 10 if deemed ready by study physicians and they are virologically negative.
During the course of treatment study evaluations will be performed to determine primary efficacy end points including viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for novel H1N1 influenza AND no clinical features of clinical failure. Evaluations will also be performed to determine secondary viral, serological, clinical efficacy, safety and pharmacokinetic endpoints.
Patients will be followed up for up to 6 months after discharge for a clinical assessment, pulmonary function and outcome of pregnancy.
The protocol will be reviewed after 6 months from starting or after 100 patients with Influenza A are recruited.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Hanoi, Vietnam
- National Institute for Infectious and Tropical Diseases (NIITD), Viet Nam
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
This is a single arm clinical and virological study assessing the use of oral oseltamivir or other agents in the treatment of patients with novel influenza A(H1N1) infection.
Any patient over 1 year of age with confirmed novel influenza A(H1N1) in whom appropriate informed consent to collect data and samples is obtained. The protocol will be reviewed after 6 months from starting or after 100 patients with new influenza A(H1N1) are recruited.
Descripción
Inclusion Criteria:
- Adults, including pregnant and breast feeding women, and Children aged ≥ 12 months when first seen with an acute febrile respiratory tract illness (ARI) of any severity and influenza A, virologically proven on a respiratory specimen according to hospital procedure, which is suspected to be novel influenza A(H1N1)
- A positive influenza A H1 swine screening reverse transcriptase polymerase chain reaction (RT PCR) or conventional PCR assay on one respiratory specimen : NPA, NP swab, nasal wash, nasal swab and throat swab
- Underlying illnesses including HIV
- Prescribed oseltamivir prior to presentation
Exclusion Criteria:
- Lack of informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for new influenza A(H1N1)
Periodo de tiempo: 12 months
|
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Viral clearance on Day 1, 2, 3, 4, 5 (H1N1) on nose and throat swab, assessed by RT PCR.
Periodo de tiempo: 12 months
|
12 months
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Jeremy Farrar, MD, Oxford University Clinical Research Unit Ho Chi Minh City Vietnam
Publicaciones y enlaces útiles
Publicaciones Generales
- Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008 Dec;21(6):626-38. doi: 10.1097/QCO.0b013e3283199797.
- Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008 Jan;41(1):13-9. doi: 10.1016/j.jcv.2007.10.020. Epub 2007 Dec 11.
- Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis. 2003 Jul 1;188(1):57-61. doi: 10.1086/375799. Epub 2003 Jun 23.
- Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. doi: 10.1586/14787210.4.5.795.
- Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SEA032
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infección por el virus de la influenza A
-
The AlfredMerck Sharp & Dohme LLCTerminadoInfección por el virus del papiloma humano | Virus del papiloma humanoAustralia
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCDesconocidoInfecciones por virus del papiloma | Vacunas contra el virus del papiloma
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... y otros colaboradoresRetiradoInfección por el virus del papiloma humanoEstados Unidos
-
Merck Sharp & Dohme LLCTerminadoInfección por el virus del papiloma humano
-
Sanford HealthTerminadoInfección por el virus del papiloma humanoEstados Unidos
-
GlaxoSmithKlineTerminadoInfección por el virus del papiloma humanoBaréin
-
Wuhan BravoVax Co., Ltd.Novotech (Australia) Pty Limited; Shanghai BravoBio Co., Ltd.Aún no reclutandoInfección por el virus del papiloma humanoAustralia
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; New York State Department of Health; Arizona Department of Health Services y otros colaboradoresTerminadoInfección por el virus del papiloma humanoEstados Unidos
-
Merck Sharp & Dohme LLCTerminado
-
Merck Sharp & Dohme LLCKaiser PermanenteTerminadoInfección por el virus del papiloma humano